Healthy life · Breakthrough Medicines
Committed to Improving Patients' Life
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies.
Our efforts are driven by our vision of delivering "Healthy life · Breakthrough Medicines ." To realize this vision, we partner with global academic institutions, investors, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record with a portfolio that includes strategically selected co-development clinical assets and internal innovative NextGen projects. We also provide technology licensing for our proprietary Harbour Mice® antibody technologies to accelerate the industry innovation in antibody therapeutics.
To advance next-generation biotherapeutics innovation, we have established three core pillars - Harbour Therapeutics, Harbour Medical, and Nona Biosciences. Harbour Therapeutics focuses on advancing a global portfolio of transformative therapeutics. Harbour Medical leverages the advantages of regional clinical development to accelerate global portfolio advancement. Nona Biosciences provides broad, open access to Harbour BioMed' s technologies and expertise through an innovative business model, accelerating global biotherapeutic innovation to benefit patients worldwide.
Dr. Jingsong Wang, is our Principal Founder, Chairman and Chief Executive Officer. Prior to founding our company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.
Michael D. Patten is Chief Strategy Officer of Harbour BioMed. Based in the United States, Michael is responsible for formulating and overseeing the global business development strategy and growth strategy for Harbour BioMed. He leads efforts to manage and strengthen Harbour BioMed's global strategic partner network and ecosystem, with a particular focus on high-potential markets outside of China, further enhancing Harbour BioMed's global presence.
Michael brings extensive experience and a strong track record in the biopharmaceutical industry. During his tenure at Bristol Myers Squibb, he held several key leadership roles. Most recently, as Head of Equity & Venture Capital, he led and managed several strategic equity investments and LP commitments across the life science ecosystem. Prior, he held roles of increasing seniority in Business Development and Alliance Leadership, successfully executing transactions and managing multiple early- and late-stage business development alliances, demonstrating exceptional expertise in business development and alliance management.
Michael holds a Bachelor of Science with Joint Honors in Pharmacology & Business Studies from the University of Edinburgh, a Master of Science in Pharmaceutical Medicine from the University of Surrey, and an MBA from the University of Maastricht (EuroMBA Consortium).
Mr. Youchen (YC) Chen is Chief Financial Officer, based in Shanghai and Hong Kong, China. At Harbour BioMed, YC is responsible for developing and managing global financial operation strategy, investments, capital markets activities and investor relations.
YC holds a Bachelor in law from Fudan University and an MBA from McDonough School of Business, Georgetown University. He is also pursuing an advanced degree at Harvard Medical School. Before taking on CFO role, he was VP of Finance, Corporate Development, IR and Strategy at Harbour BioMed and successfully led a series of landmark transactions with global partners. Prior to Harbour BioMed, he was CFO at a clinical-stage radiopharmaceutical startup and also worked as Vice President at Credit Suisse China Investment Banking and Capital Market team, advising Greater China healthcare and tech companies on strategic and financing transactions. Prior to rejoining Credit Suisse, he worked as Head of Corporate Finance at Yidu Tech (2158. HK) and audit assistant manager at KPMG.
Dr. Ian Y. Liu is Senior Vice President, Global Head of Legal of Harbour BioMed. Based in the United States, Dr. Liu oversees business development transactions, ensuring legal and regulatory compliance while facilitating seamless execution to safeguard the company's interests. He also leads the company's global intellectual property strategy. Additionally, Dr. Liu takes full responsibility for U.S. -related legal affairs, managing significant legal matters, including lawsuits, protecting the company's business operations in the region, and supporting its strategic growth in the U.S. market.
Before joining Harbour BioMed, Dr. Liu worked at renowned law firms, including Finnigan, Henderson, Farabow, Garrett & Dunner, LLP, and K&L Gates, LLP, where he gained extensive experience in patent applications, litigation, and due diligence. In the corporate legal affairs sector, he held key positions such as Head of Legal and Governmental Affairs at Simcere Pharmaceutical, demonstrating exceptional ability in handling complex legal matters and commercial negotiations.
Dr. Liu holds a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a J.D. from Suffolk University Law School.
Dr. Bob Zhang is President of Metabolic Disease Franchise at Harbour BioMed. Based in Shanghai, he leads the franchise's strategy and operations, overseeing portfolio development, research and development, organizational growth, strategic collaborations, and NewCo incubation to accelerate the delivery of transformative therapies for patients.
Dr. Zhang is a physician-scientist and biotech entrepreneur with more than 20 years of leadership experience in metabolic and liver disease research and development. Prior to joining Harbour BioMed, he served as Co-founder and Chief Executive Officer of Epigenic Therapeutics, Chief Executive Officer of Kunming Biomed International, and Director of Translational Medicine at Sanofi. Throughout his career, he has led drug discovery, translational pharmacology, and early clinical development programs across biotechnology companies, multinational pharmaceutical organizations, and CROs, while also contributing to biotech company formation, strategy, and growth.
Dr. Zhang received his M.D. from Dalian Medical University and his Ph.D. from the University of Sydney, and completed executive management training at CEIBS (China Europe International Business School).
Dr. Jenny Xie is Chief Scientific Officer, Immunology and Head of Global External Innovation of Harbour BioMed. Based in Shanghai, she is responsible for Harbour BioMed's global external innovation strategy in immunology, managing ongoing strategic collaborations with key partners, as well as identifying and pursuing new partnership opportunities. Additionally, she will oversee all activities at the company's Harbour BioMed-AstraZeneca Innovation Lab in Beijing.
Dr. Xie brings more than 25 years of experience in the biopharmaceutical industry. Prior to joining Harbour BioMed, she served as Executive Director and Head of Discovery Immunology at Bristol Myers Squibb, where she led research efforts in autoimmune diseases and contributed to the discovery, evaluation, and clinical translation of novel therapeutic approaches. Prior to that, she also held scientific leadership roles at Merck, building extensive experience in early-stage research and development.
Dr. Xie received her Ph.D. in Immunology from Boston University School of Medicine and her bachelor's degree in Biology from Fudan University.
Dr. Eric Liu is Chief Operating Officer (COO) and Head of Clinical Development, Neuroscience at Harbour BioMed. Based in Shanghai, Dr. Liu leads the clinical development strategy for Harbour BioMed’s neuroscience portfolio while overseeing company-wide operations. He is responsible for advancing global clinical trial execution, driving operational excellence across functions, supporting fundraising initiatives, and working closely with Harbour BioMed’s executive leadership team to advance the Company’s strategic goals in neuroscience therapeutics.
Dr. Liu is a physician-scientist and biopharma executive with more than 15 years of global experience in clinical development, translational research, and medical affairs. Previously, he held research positions at the University of California, Los Angeles (UCLA) and the Ohio State University Medical Center, where he led clinical trials sponsored by leading global pharmaceutical companies, including Merck, Pfizer, and Eli Lilly.
Following his return to China, Dr. Liu served as Chief Medical Officer at Apeloa Pharmaceutical and was a co-founder of Brise Pharmaceuticals. In these roles, he established and led clinical development teams, advanced dual regulatory filings in China and the United States, and supported financing activities across multiple therapeutic areas, including central nervous system (CNS), oncology, and cardiovascular diseases.
Dr. Liu received his Ph.D. in neuroscience and his bachelor’s degree in clinical medicine from Zhejiang University School of Medicine.
Veronica Xia is Global Chief Operating Officer and China General Manager, Harbour Medical, at Harbour BioMed.
Harbour Medical is building an AI-powered clinical development platform with ecosystem-level advantages in China — high-quality trial sites, top principal investigators, and large patient populations — combined with co-development models that retain significant upside. Veronica leads global clinical operations, driving efficiency, productivity, and execution quality across our partnerships.
Veronica brings over 25 years of experience across Fortrea, Labcorp, IQVIA/Quintiles, Eli Lilly, Sanofi-Aventis, and Roche — including more than a decade as China General Manager at leading global clinical development organizations. She has a proven track record of scaling operations from start-up to full maturity and building high-performance teams. She holds an MBA from Shanghai University of Finance and Economics and a Bachelor of Clinical Medicine from Shanghai Jiao Tong University School of Medicine.
Dr. Spyros Papapetropoulos is the Chief Executive Officer of Barrier Neurotherapeutics. As part of Harbour BioMed’s venture creation strategy of building dedicated Newcos around high-conviction therapeutic areas, Barrier Neurotherapeutics will focus on advancing a differentiated neuroscience portfolio—leveraging novel antibody-based modalities and the Harbour Mice® platform to pursue highly differentiated opportunities. Dr. Papapetropoulos will lead this venture end-to-end, with responsibility for corporate strategy, pipeline architecture, capital raising, team building, and external partnerships.
Dr. Papapetropoulos is a seasoned biotech CEO and board-certified neuroscience physician with over 20 years of experience building companies from formation through IND, clinical execution, and exit. Most recently, he served as President & CEO of Neuphoria Therapeutics (NASDAQ: NEUP). He previously held executive leadership roles at Vigil Neurosciences, SwanBio, Cavion (acquired by Jazz Pharmaceuticals), Teva, Acadia, Pfizer, and Allergan.
Dr. Papapetropoulos holds an M.D. and a Ph.D. in Neuroscience from the University of Patras, Greece, and has authored over 220 peer-reviewed publications.
Dr. Ian B. Walters is Chief Executive Officer of Blue Ocean Medicines. He leads Blue Ocean Medicines in the U.S., sourcing strong early-stage programs globally along with fundraising and business development, and bringing them to Harbour Medical to develop.
Dr. Walters is a physician-scientist, entrepreneur, and biotech executive with more than 25 years of global experience spanning drug development, translational medicine, and corporate strategy. He has led clinical development of over 30 therapeutic programs across oncology, immunology, and rare diseases, contributing to five FDA-approved oncology drugs. He began his career as a Lead Clinical Investigator at The Rockefeller University, where he collaborated with Nobel Laureate Dr. Ralph Steinman and Dr. James Krueger on translational immunology research, and later held senior roles at Protein Design Labs, Millennium Pharmaceuticals, and Bristol-Myers Squibb, where he served as Executive Director of Global Oncology Clinical Research.
Dr. Walters has founded and led eight life science companies, including Portage Biotech (NASDAQ: PRTG) and SalvaRx (LON: SALV). Prior to joining Harbour BioMed, he served as Founder and CEO of Value Driven Drug Development Solutions. During his career, Dr. Walters has raised more than $100 million from public and private investors, performed due diligence on over 800 technologies and companies, and managed global P&L exceeding $500 million.
Dr. Walters received his M.D. from Albert Einstein College of Medicine, his MBA from the Wharton School at the University of Pennsylvania, and his B.S. in Biology from the State University of New York at Albany.
Dr. Kevin Heller is a Venture Partner, Oncology at Harbour BioMed. A physician-scientist and drug developer, he has more than 20 years of experience in oncology research across academia and industry, spanning the full spectrum of oncology drug development—from discovery and pre-IND through clinical development, commercialization, and business development.
Dr. Heller trained as a Pediatric Oncology Fellow at Memorial Sloan Kettering Cancer Center and later served as an Instructor in Clinical Investigation at The Rockefeller University, where he conducted research in tumor immunology and translational medicine. He then spent six years at Bristol-Myers Squibb, holding roles including Associate Director, Oncology & Immunology; Director, Oncology Medical Strategy; and Global Lead, Oncology Search, Evaluation and Diligence. He subsequently served as Senior Medical Director at AstraZeneca and as Vice President, Head of Antibody Clinical Development in Immuno-Oncology at Incyte.
Dr. Heller has held senior leadership positions at multiple biopharmaceutical companies, including NextCure, Tallac Therapeutics, and Jasper Therapeutics. He is currently a Fractional Chief Medical Officer at Stealth Biotech and SSI Strategy, and an advisor to the investment team at Ausangate Capital.
Dr. Heller received his M.D. from The George Washington University School of Medicine and Health Sciences and his B.S. in Molecular Biophysics and Biochemistry from Yale University.
Dr. Timothy Zheng is a Venture Partner, Immunology at Harbour BioMed. An accomplished scientist and passionate drug hunter with 25 years of industry experience spanning large pharma, biotech, and VC-backed startups, Tim has a proven track record of delivering preclinical programs to development stage across immunology & inflammation, fibrosis, and immuno-oncology, with more than 10 development candidate nominations including Vixarelimab (anti-OSMR mAb), currently in Phase 3 clinical trials for Systemic Sclerosis, as well as BI770371 (anti-SIRPα antagonist mAb) and BI765250 (anti-PD-1 agonist mAb).
Dr. Zheng’s drug discovery & development expertise spans diverse therapeutic modalities, including biologics of various formats and small molecule discovery ranging from traditional kinase inhibitors to novel heterobifunctional small molecule-induced proximity modalities. He most recently served as Founder and Principal of TSZBioConsulting LLC, providing consultation services for biotech startups and VC firms. He previously served as Chief Scientific Officer and Founding Member of Ecliptic Bio, where he co-led Series A fundraising and achieved two Development Candidate selections within only 18 months. Earlier in his career, he held senior leadership roles at Siduma Therapeutics, Sonata Therapeutics, Boehringer Ingelheim, and Biogen, where he led immunology and fibrosis drug discovery, directed global immune modulation portfolios, and contributed to multiple INDs, BLA filings, as well as in- and out-licensing deals.
Dr. Zheng holds a Ph.D. in Immunology from Yale University and a B.S. in Nuclear Chemistry from Fudan University. He has authored over 80 publications and patents, and organized multiple scientific conferences, including most recently a Nature Café Symposium on Stromal & Immune Cell Interactions.
Robert Kamen, Ph.D., has served on our scientific advisory board since 2016. Dr. Kamen is an Advisory Partner at Third Rock Ventures. In 2005, he co-founded BioAssets Development Corporation and served as its Chairman. He currently serves as an Independent Non-Executive Director of the Company and a Director of Jounce Therapeutics. He was previously a Director of Neon Therapeutics and Harbour Antibodies. Earlier in his career, he was Senior Vice President of Scientific Affairs at the pioneering biotechnology firm named Genetics Institute, Inc. Dr. Kamen received his bachelor's degree in biophysics from Amherst College, a Ph.D. in biochemistry and molecular biology from Harvard University Graduate School of Arts and Sciences. During his academic scientific career, he worked at the Imperial Cancer Research Fund.
Jon Wigginton, M.D., has served on our scientific advisory board since May 2020. Dr. Wigginton currently serves as Chief Medical Officer, Cullinan Oncology, and Advisor, MPM Capital. He previously served as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a Maryland biotechnology company focused on immunotherapeutic approaches for cancer and autoimmune disease. Prior to MacroGenics, Dr. Wigginton served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1 among others. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic, translational and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer.
Robert Kramer, Ph.D., has served on our scientific advisory board since December 2016. Dr. Kramer serves as CSO of Portage Biotech Inc. Dr. Kramer previously served as Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnson and Johnson), where he was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Prior to joining Janssen Research & Development, LLC, Dr. Kramer served as VP Drug Discovery and Research for Bristol-Myers Squibb (BMS), where he provided scientific leadership and strategic oversight for many pre-clinical Oncology and Immunology programs and projects that entered development. Dr. Kramer was previously an Assistant Professor at Harvard Medical School. Dr. Kramer received his Ph.D. in pharmacology from the University of Vermont and completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health.
Peter Moesta, Ph.D., has served on our scientific advisory board since December 2016. He oversaw the development, production and worldwide launch of important medicines, such as Humira, Yervoy and Opdivo. Dr. Moesta previously served in executive roles at Bristol-Myers Squibb.
Zhigang Tian, Ph.D., has served on our scientific advisory board since August 2020. Dr. Tian is an academician of Chinese Academy of Engineering, a member of Academia Europaea and a medical immunologist. Currently, he is a professor at University of Science and Technology of China (USTC), where he also works as Dean at School of Basic Medical Sciences, and Director at Institute of Immunology. He is also the Director of the Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science.
Dr. Tian was awarded with the National Science Fund for Distinguished Young Scholars. He is the Academic Leader of Chang Jiang Scholars Program as well as the Innovation Research Program of National Natural Science Foundation of China. Dr. Tian is Head of National Science and Technology Major Project and Chief Scientist of National Major Research Plan Program.
Dr. Tian's laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK)cells,particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy.
Dr. Salter-Cid brings over 20 years of outstanding leadership experience in the biotech and pharmaceutical industries, having held senior executive roles at Flagship Pioneering, Bristol Myers Squibb (BMS), and Gossamer Bio. Her expertise spans Immunology and Immuno-Oncology, where she has established a prolific track record of translating scientific insights into clinical-stage assets.
Dr. Salter-Cid currently serves as Venture Partner at Osage University Partners (OUP), a premier venture capital firm focused on investing in startups that commercialize university research. Prior to that, she served as Chief Scientific Officer of Pioneering Medicines at Flagship Pioneering, where she was responsible for pioneering a portfolio of groundbreaking medicines sourced from the broad spectrum of scientific platforms within the Flagship ecosystem. Before joining Flagship, she served as Chief Scientific Officer at Gossamer Bio, where she was instrumental in building the company's portfolio of immunology and immuno-oncology programs.
Dr. Salter-Cid's tenure at Bristol Myers Squibb further highlights her outstanding capabilities. During her 13 years there, she most recently served as Vice President and Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery. In this capacity, she led teams that successfully advanced over 20 compounds into clinical development, demonstrating her outstanding ability to drive innovation from discovery to the clinic. Throughout her career, Dr. Salter-Cid has authored more than 90 publications and patents.
Dr. Patel brings an outstanding track record of therapeutic innovation spanning over two decades in industry and academia. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology.
Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice President and Chief Scientific Officer of UCB, where he and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®) and zilucoplan (Zilbrysq®). Prior to UCB, he spent 10 years at Novartis, most recently as the Head of Research of the Novartis Institutes for BioMedical Research (NIBR) Europe. During his tenure, he led research in the autoimmune, transplantation, and inflammation disease areas, contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV.
Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board certified in internal medicine, rheumatology, and allergy & immunology.
Dr. Klickstein brings more than two decades of leadership experience spanning biopharmaceutical innovation, translational research, and clinical medicine. He currently serves as Chief Executive Officer of Koslapp Therapeutics. He co-founded Versanis Bio, where he held multiple executive leadership positions before the company was acquired by Eli Lilly and Company. Before that, he served as Chief Innovation Officer at Adicet Bio and Chief Scientific Officer of resTORbio (Adicet's predecessor company), and was an independent board member of Blade Therapeutics. Prior to that, he spent more than a decade at Novartis, where he led the New Indications Discovery Unit within the Novartis Institutes for BioMedical Research, focused on identifying and evaluating novel therapeutic targets. Before transitioning to industry, Dr. Klickstein was a physician-scientist at Harvard Medical School's Brigham and Women's Hospital, where he led an NIH-funded basic science laboratory while maintaining a clinical practice.
宗忱博士任和铂医药总裁。他常驻上海，全面负责强化和铂医药内部产品管线，推进整体产品组合的战略布局，并主导资产策略及对外合作事务。同时，他还将统筹跨部门协作，加快项目开发进程，最大限度地提升公司管线的整体价值。
宗博士拥有逾20年的全球生物制药行业领导经验，在产品组合战略、商业运营及业务拓展方面成绩斐然，曾先后服务于跨国制药巨头及新兴生物技术企业。加入和铂医药之前，宗博士曾担任ARC NOUVEL临床开发咨询公司首席顾问。他还曾作为创始首席执行官，领导恒瑞医药美国子公司（HENGRUI THERAPEUTICS U.S.）的全球业务拓展工作。更早之前，他曾在默沙东、百时美施贵宝、 先灵葆雅及辉瑞担任高级管理职务，负责管理全球业务板块、统筹大规模商业产品组合，并主导了多项重大业务拓展、许可引进及并购交易。
